Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
Induction treatment for male and female pediatric Hodgkin Lymphoma (EuroNet-PHL protocol).
Second-line therapy for Gemcitabine-refractory Advanced Pancreatic Cancer.
Induction therapy for pediatric female patients with Hodgkin Lymphoma.
Relapsed or refractory B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, or Multiple Myeloma.
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Approved for use in oncology care according to FDA-approved indications.
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Approved for use in oncology care according to FDA-approved indications.
BRAF V600E/K mutation-positive Melanoma, Non-Small Cell Lung Cancer, Anaplastic Thyroid Cancer, and Colorectal Cancer.
Myelofibrosis, Polycythemia Vera, and acute/chronic Graft-versus-Host Disease (GVHD).
Deleterious BRCA-mutated or HRD-positive Ovarian, Breast, Pancreatic, and Prostate Cancers.
Approved for use in oncology care according to FDA-approved indications.